Correction to: The impact of COVID-19 on systemic anticancer treatment delivery in Scotland.

Baxter, Mark A; Murphy, John; Cameron, David; Jordan, Judith; Crearie, Christine; Lilley, Christina; Sadozye, Azmat; Maclean, Mary; Hall, Peter; Phillips, Angela; Greger, Alex; Madeleine, Jude; Petty, Russell D

Baxter, Mark A; Murphy, John; Cameron, David; Jordan, Judith; Crearie, Christine; Lilley, Christina; Sadozye, Azmat; Maclean, Mary; Hall, Peter; Phillips, Angela; Greger, Alex; Madeleine, Jude; Petty, Russell D.

Afiliação

Baxter MA; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Murphy J; Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK.
Cameron D; NHS Lanarkshire, South Lanarkshire, UK.
Jordan J; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
Crearie C; Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK.
Lilley C; NHS Grampian, Aberdeen, UK.
Sadozye A; West of Scotland Cancer Network, Glasgow, UK.
Maclean M; Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK.
Hall P; West of Scotland Cancer Network, Glasgow, UK.
Phillips A; West of Scotland Cancer Network, Glasgow, UK.
Greger A; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
Madeleine J; Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK.
Petty RD; Tayside Cancer Centre, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK.

Br J Cancer ; 124(10): 1745, 2021 May.

Article em En | MEDLINE | ID: mdl-33723400

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Br J Cancer Ano de publicação: 2021 Tipo de documento: Article